Aldeyra Therapeutics, Inc. (ALDX) Stock Price
ALDXStock
$1.49−74.66%52W
Market Cap$89.58M
P/E—
PEG Ratio—
Div yield—
Beta1.19
ALDX Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-83.43%
Price vs S&P 500 (4W)-4.48%
VGM Score22.75
ALDX Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.08 | -$0.09 | -16.13%(-$0.01) | |
| Q1 2026 | -$0.12 | -$0.06 | +50.00%(+$0.06) | |
| Q4 2025 | -$0.14 | -$0.10 | +31.03%(+$0.04) | |
| Q3 2025 | -$0.16 | -$0.13 | +17.46%(+$0.03) | |
| Q2 2025 | -$0.19 | -$0.16 | +14.67%(+$0.03) |
ALDX Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.25
4.25
4.25
4.25
Industry Peers — Pharmaceuticals(570)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ALDXAldeyra Therapeutics, Inc. | — | — | D | $1.49 |
| LLYEli Lilly & Co. | D | B | C | $1174.61 |
| JNJJohnson & Johnson | D | C | B | $268.04 |
| ABBVABBVIE INC. | D | C | B | $255.48 |
| MRKMerck & Co., Inc. | D | C | B | $148.35 |
| NVSNovartis AG | C | C | C | $153.81 |
| AZNAstraZeneca PLC | C | B | C | $162.70 |
| NVONovo-Nordisk A/S | B | C | C | $45.61 |
| ABTAbbott Laboratories | C | C | C | $112.47 |
| PFEPfizer Inc. | C | D | B | $27.96 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $541.69 |
About Aldeyra Therapeutics, Inc.
Aldeyra Therapeutics is a clinical-stage biotechnology company developing medicines for immune-mediated and metabolic diseases. Its lead candidate, Reproxalap, is in late-stage development for dry eye disease and allergic conjunctivitis. The company's pipeline also includes candidates targeting retinal diseases, autoimmune conditions, and cancer.